Nikoletta Nagy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nikoletta Nagy has a total of 474 co-authors. Here are the top co-authors by number of shared publications:
- Márta Széll
Department of Medical Genetics, University of Szeged, Szeged, Hungary; HUN-REN-SZTE Functional Clinical Genetics Research Group, Szeged, Hungary
26 shared publications Márta Széll
Department of Medical Genetics, University of Szeged, Szeged, Hungary; ELKH-SZTE Functional Clinical Genetics Research Group, Eötvös Loránd Research Network, Szeged, Hungary
17 shared publications- Margit Pál
Department of Medical Genetics, University of Szeged, 6720 Szeged, Hungary
12 shared publications Katalin Farkas
Department of Medical Genetics University of Szeged Szeged Hungary
10 shared publications- Lajos Kemény
Department of Dermatology and Allergology University of Szeged Szeged Hungary
9 shared publications Kornélia Tripolszki
Univ Szeged, Dept Med Genet, 4 Somogyi Bela St, H-6720 Szeged, Hungary
8 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (11) , 3201-3203
The importance of challenging dogma with patient data
- 15 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (11) , 3201-3203
Open AccessThe importance of challenging dogma with patient data
- Open Access
- 4 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1130-1141
Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
CYLD cutaneous syndrome (CCS) skin tumours develop from puberty onwards, can number in the hundreds and progressively grow over time. CCS patients lack medical therapies and require repeated surgery to control tumour burden. CYLD loss of heterozygosity (LOH) drives tumour growth, and CCS tumours have previously been shown to demonstrate increased canonical NF-κB and Wnt signalling. Here, we demonstrate evidence of non-canonical NF-κB signalling in CCS tumour keratinocytes, with increased p100 to p52 processing and RelB protein expression compared to normal skin. Utilizing complementary transcriptomics and proteomics on patient derived CCS tumour cell fractions, we identify IκB kinase alpha (IKKα) as a candidate target in the non-canonical NF-κB signalling pathway. A novel, highly selective, IKKα inhibitor (SU1644) used in patient derived CCS tumour spheroid cultures demonstrated that IKKα inhibition reduced tumour spheroid viability. These data provide the pre-clinical rationale for the assessment of topical IKKα inhibitors as a novel preventative treatment for CCS.
- 4 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1130-1141
Open AccessTargeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
CYLD cutaneous syndrome (CCS) skin tumours develop from puberty onwards, can number in the hundreds and progressively grow over time. CCS patients lack medical therapies and require repeated surgery to control tumour burden. CYLD loss of heterozygosity (LOH) drives tumour growth, and CCS tumours have previously been shown to demonstrate increased canonical NF-κB and Wnt signalling. Here, we demonstrate evidence of non-canonical NF-κB signalling in CCS tumour keratinocytes, with increased p100 to p52 processing and RelB protein expression compared to normal skin. Utilizing complementary transcriptomics and proteomics on patient derived CCS tumour cell fractions, we identify IκB kinase alpha (IKKα) as a candidate target in the non-canonical NF-κB signalling pathway. A novel, highly selective, IKKα inhibitor (SU1644) used in patient derived CCS tumour spheroid cultures demonstrated that IKKα inhibition reduced tumour spheroid viability. These data provide the pre-clinical rationale for the assessment of topical IKKα inhibitors as a novel preventative treatment for CCS.
- Open Access
- 3 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2358
A Unique Patient Stratification Method Combined with a Machine Learning Approach Identifies Novel Genetic Susceptibility and Protective Factors for Severe COVID-19 in a Hungarian Population
Intensive research has shown that severe COVID-19 outcomes are influenced by antiviral pathways and immune responses, both shaped by genetic predisposition. In this study, we aimed to identify genetic variants associated with disease severity in a cohort of Hungarian patients. We applied a novel stratification method based on age, disease severity, and clinical background to classify patients by susceptibility to severe COVID-19. Whole-exome sequencing (WES) was performed on 168 individuals, and gene mutation loads were assessed. Using a Random Forest machine learning approach, we identified variants of 877 genes that distinguished between severe and non-severe cases. We further categorized these genes as either susceptibility or protective factors. Gene-set enrichment analysis highlighted the most affected biological pathways. Our findings support the development of personalized diagnostic tools to assess the risk of severe COVID-19 and guide targeted treatment strategies. Our findings further extend the results of previous studies, providing novel insights into the genetic determinants of COVID-19 severity.
- 3 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2358
Open AccessA Unique Patient Stratification Method Combined with a Machine Learning Approach Identifies Novel Genetic Susceptibility and Protective Factors for Severe COVID-19 in a Hungarian Population
Intensive research has shown that severe COVID-19 outcomes are influenced by antiviral pathways and immune responses, both shaped by genetic predisposition. In this study, we aimed to identify genetic variants associated with disease severity in a cohort of Hungarian patients. We applied a novel stratification method based on age, disease severity, and clinical background to classify patients by susceptibility to severe COVID-19. Whole-exome sequencing (WES) was performed on 168 individuals, and gene mutation loads were assessed. Using a Random Forest machine learning approach, we identified variants of 877 genes that distinguished between severe and non-severe cases. We further categorized these genes as either susceptibility or protective factors. Gene-set enrichment analysis highlighted the most affected biological pathways. Our findings support the development of personalized diagnostic tools to assess the risk of severe COVID-19 and guide targeted treatment strategies. Our findings further extend the results of previous studies, providing novel insights into the genetic determinants of COVID-19 severity.
- Open Access
- 24 December 2025
- Published by Elsevier in JID Innovations
- Vol. 6 (2) , 100445
Population- and haplotype-dependent variation around TYR rs1126809: An in silico study for melanoma risk research
- 24 December 2025
- Published by Elsevier in JID Innovations
- Vol. 6 (2) , 100445
Open AccessPopulation- and haplotype-dependent variation around TYR rs1126809: An in silico study for melanoma risk research
- Open Access
- 30 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10553
A Novel Germline Frameshift Variant in the Tumor Suppressor Gene OBSCN in a Melanoma Patient
Malignant melanoma is a complex malignancy with genetic, environmental, and lifestyle factors in its etiology. While germline variants in melanoma predisposition genes have been described, many patients remain genetically unexplained after panel testing. We previously analyzed a Hungarian melanoma cohort (n = 17), identifying variants in predisposing or susceptibility genes in 58.82% of patients. For individuals negative on this melanoma-specific panel, we expanded testing to a 19-gene panel associated with multiple cancer types. Next-generation sequencing was performed, followed by Sanger sequencing for confirmation. Variants were classified according to ACMG guidelines. In a 58-year-old female patient with a history of primary cutaneous melanoma, we identified a novel heterozygous frameshift variant in the tumor suppressor gene OBSCN (c.21322_21323insCTGG, p.G7108AfsTer10; NM_001386125.1). This insertion introduces a premature stop codon in exon 89 within the immunoglobulin-like domain, predicting protein truncation. Classified as likely pathogenic (PVS1, PM2), the variant is absent from population databases. To date, somatic OBSCN mutations have been reported in melanoma. This first report of a germline OBSCN frameshift variant in melanoma expands the genetic landscape of melanoma predisposition and suggests that OBSCN may represent a candidate gene contributing to melanoma risk.
- 30 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10553
Open AccessA Novel Germline Frameshift Variant in the Tumor Suppressor Gene OBSCN in a Melanoma Patient
Malignant melanoma is a complex malignancy with genetic, environmental, and lifestyle factors in its etiology. While germline variants in melanoma predisposition genes have been described, many patients remain genetically unexplained after panel testing. We previously analyzed a Hungarian melanoma cohort (n = 17), identifying variants in predisposing or susceptibility genes in 58.82% of patients. For individuals negative on this melanoma-specific panel, we expanded testing to a 19-gene panel associated with multiple cancer types. Next-generation sequencing was performed, followed by Sanger sequencing for confirmation. Variants were classified according to ACMG guidelines. In a 58-year-old female patient with a history of primary cutaneous melanoma, we identified a novel heterozygous frameshift variant in the tumor suppressor gene OBSCN (c.21322_21323insCTGG, p.G7108AfsTer10; NM_001386125.1). This insertion introduces a premature stop codon in exon 89 within the immunoglobulin-like domain, predicting protein truncation. Classified as likely pathogenic (PVS1, PM2), the variant is absent from population databases. To date, somatic OBSCN mutations have been reported in melanoma. This first report of a germline OBSCN frameshift variant in melanoma expands the genetic landscape of melanoma predisposition and suggests that OBSCN may represent a candidate gene contributing to melanoma risk.
- Open Access
- 4 July 2025
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 1
Frequent cutaneous manifestations of rare monogenic dental diseases: a review of OMIM data and cases from own clinical practice
In the last two decades, the elucidation of the genetic background of monogenic dental diseases has been significantly enhanced. In the Online Mendelian Inheritance in Man (OMIM) database there are 144 isolated or syndromic ones. Out of this 55 rare monogenic dental diseases (38%) are accompanied by cutaneous manifestations. In this study, we review the group of rare monogenic diseases with dental and cutaneous manifestations and observed the most frequent skin findings (hypohidrosis, hyperkeratosis, dry skin and skin fragility), nail symptoms (dysplastic nails and hypoplastic nails) and hair abnormalities (sparse hair, alopecia and hypertrichosis) and highlighted the genes associated with these frequent clinical features. We also summarized the frequent dental anomalies (missing teeth, abnormal shape of teeth, enamel abnormalities and delayed eruption or uneruption of teeth). Among the additional non-dental and non-cutaneous manifestations ophthalmological, skeletal and otorhinolaryngological abnormalities are the most frequently developing ones. Regarding the genetic background, there are 42 disease-causing genes associated with the 55 entities. Here, we also highlighted the WNT10A , CTSC and EDA1 associated diseases in order to demonstrate how different variants of these genes can lead to the development of different phenotypes. Reviewing rare monogenic dental-cutaneous diseases, the association of the identified special clinical features may raise the attention of the specialist in everyday clinical parctice and help in the identification of the underlying genetic background.
- 4 July 2025
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 1
Open AccessFrequent cutaneous manifestations of rare monogenic dental diseases: a review of OMIM data and cases from own clinical practice
In the last two decades, the elucidation of the genetic background of monogenic dental diseases has been significantly enhanced. In the Online Mendelian Inheritance in Man (OMIM) database there are 144 isolated or syndromic ones. Out of this 55 rare monogenic dental diseases (38%) are accompanied by cutaneous manifestations. In this study, we review the group of rare monogenic diseases with dental and cutaneous manifestations and observed the most frequent skin findings (hypohidrosis, hyperkeratosis, dry skin and skin fragility), nail symptoms (dysplastic nails and hypoplastic nails) and hair abnormalities (sparse hair, alopecia and hypertrichosis) and highlighted the genes associated with these frequent clinical features. We also summarized the frequent dental anomalies (missing teeth, abnormal shape of teeth, enamel abnormalities and delayed eruption or uneruption of teeth). Among the additional non-dental and non-cutaneous manifestations ophthalmological, skeletal and otorhinolaryngological abnormalities are the most frequently developing ones. Regarding the genetic background, there are 42 disease-causing genes associated with the 55 entities. Here, we also highlighted the WNT10A , CTSC and EDA1 associated diseases in order to demonstrate how different variants of these genes can lead to the development of different phenotypes. Reviewing rare monogenic dental-cutaneous diseases, the association of the identified special clinical features may raise the attention of the specialist in everyday clinical parctice and help in the identification of the underlying genetic background.
- 17 April 2025
- Published by Elsevier in Journal of Dermatological Science
- Vol. 118 (3) , 101-103
Oculocutaneous albinism type 1B associated with allelic combination of a risk haplotype
- 17 April 2025
- Published by Elsevier in Journal of Dermatological Science
- Vol. 118 (3) , 101-103
Oculocutaneous albinism type 1B associated with allelic combination of a risk haplotype
- Open Access
- 13 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1583
Novel Pathogenic Variant of the TRRAP Gene Detected in a Hungarian Family with Autosomal Dominant Non-Syndromic Hearing Loss
Autosomal dominant non-syndromic hearing loss (ADNSHL) is a genetically heterogenic condition. The transformation/transcription domain associated protein (TRRAP) gene has been recently associated with ADNSHL, and only four variants of the gene have so far been reported in this disease. Here, we report on a Hungarian ADNSHL family in which the affected individuals exhibited sensorineural hearing loss with similar clinical symptoms, including initial impaired high frequencies that subsequently affected speech and lower frequencies. Whole exome sequencing and screening of the shared genetic variants of the affected individuals was performed. Our results revealed a novel heterozygous missense variant (NM_001244580.2, c.5360A>G, p.Lys1787Arg) in the TRRAP gene. This variant is completely co-segregated with hearing impairment. It is present in a heterozygous form in the affected mother and daughter but not carried by any unaffected family members. This study highlights the importance of elucidating the germline genetic background of ADNSHL, which may help to predict individual risk and the risk of family members. This will improve prevention, screening, and therapeutic measures for each patient and hearing loss-prone families.
- 13 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1583
Open AccessNovel Pathogenic Variant of the TRRAP Gene Detected in a Hungarian Family with Autosomal Dominant Non-Syndromic Hearing Loss
Autosomal dominant non-syndromic hearing loss (ADNSHL) is a genetically heterogenic condition. The transformation/transcription domain associated protein (TRRAP) gene has been recently associated with ADNSHL, and only four variants of the gene have so far been reported in this disease. Here, we report on a Hungarian ADNSHL family in which the affected individuals exhibited sensorineural hearing loss with similar clinical symptoms, including initial impaired high frequencies that subsequently affected speech and lower frequencies. Whole exome sequencing and screening of the shared genetic variants of the affected individuals was performed. Our results revealed a novel heterozygous missense variant (NM_001244580.2, c.5360A>G, p.Lys1787Arg) in the TRRAP gene. This variant is completely co-segregated with hearing impairment. It is present in a heterozygous form in the affected mother and daughter but not carried by any unaffected family members. This study highlights the importance of elucidating the germline genetic background of ADNSHL, which may help to predict individual risk and the risk of family members. This will improve prevention, screening, and therapeutic measures for each patient and hearing loss-prone families.
- Open Access
- 7 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (8) , 2094-2098.e7
Truncating CYLD Pathogenic Variants in CYLD Cutaneous Syndrome Distinctly Influence CYLD Proteostasis and NF-κB Signaling
- 7 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (8) , 2094-2098.e7
Open AccessTruncating CYLD Pathogenic Variants in CYLD Cutaneous Syndrome Distinctly Influence CYLD Proteostasis and NF-κB Signaling
- Open Access
- 13 January 2025
- Published by MDPI AG in Preprints.org
Novel Pathogenic Variant of the TRRAP Gene Detected in a Hungarian Family with Autosomal Dominant Non-Syndromic Hearing Loss
Autosomal dominant non-syndromic hearing loss (ADNSHL) is a genetically heterogenic condition. The transformation/transcription domain associated protein (TRRAP) gene has been recently associated with ADNSHL and only four variants of the gene have so far been reported in this disease. (1) Here, we report on a Hungarian ADNSHL family, in which the affected individuals exhibited sensorineural hearing loss with similar clinical symptoms, including initial impaired high frequencies that subsequently affected speech and lower frequencies. (2) Whole exome sequencing and screening of the shared genetic variants of the affected individuals was performed. (3) Our results revealed a novel heterozygous missense variant (NM_001244580.2, c.5360A>G, p.Lys1787Arg) in the TRRAP gene. This variant is completely co-segregated with hearing impairment. It is present in a heterozygous form in the affected mother and daughter, but not carried by any unaffected family members. (4) This study highlights the importance of elucidating the germline genetic background of ADNSHL, which may help to predict individual risk and the risk of family members. This will improve prevention, screening and therapeutic measures for each patient and hearing loss-prone families.
- 13 January 2025
- Published by MDPI AG in Preprints.org
Open AccessNovel Pathogenic Variant of the TRRAP Gene Detected in a Hungarian Family with Autosomal Dominant Non-Syndromic Hearing Loss
Autosomal dominant non-syndromic hearing loss (ADNSHL) is a genetically heterogenic condition. The transformation/transcription domain associated protein (TRRAP) gene has been recently associated with ADNSHL and only four variants of the gene have so far been reported in this disease. (1) Here, we report on a Hungarian ADNSHL family, in which the affected individuals exhibited sensorineural hearing loss with similar clinical symptoms, including initial impaired high frequencies that subsequently affected speech and lower frequencies. (2) Whole exome sequencing and screening of the shared genetic variants of the affected individuals was performed. (3) Our results revealed a novel heterozygous missense variant (NM_001244580.2, c.5360A>G, p.Lys1787Arg) in the TRRAP gene. This variant is completely co-segregated with hearing impairment. It is present in a heterozygous form in the affected mother and daughter, but not carried by any unaffected family members. (4) This study highlights the importance of elucidating the germline genetic background of ADNSHL, which may help to predict individual risk and the risk of family members. This will improve prevention, screening and therapeutic measures for each patient and hearing loss-prone families.